Biostage, Inc. (BSTG)
Total Valuation
Biostage has a market cap or net worth of $68.70 million. The enterprise value is $65.82 million.
| Market Cap | 68.70M |
| Enterprise Value | 65.82M |
Important Dates
The next earnings date is Tuesday, March 28, 2023, after market close.
| Estimated Earnings Date | Mar 28, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Biostage has 11.64 million shares outstanding. The number of shares has increased by 15.99% in one year.
| Shares Outstanding | 11.64M |
| Shares Change (YoY) | +15.99% |
| Shares Change (QoQ) | +3.43% |
| Owned by Insiders (%) | 50.96% |
| Owned by Institutions (%) | n/a |
| Float | 5.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 31.10 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.21 |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -47.80%.
| Return on Equity (ROE) | -47.80% |
| Return on Assets (ROA) | -28.85% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.47% in the last 52 weeks. The beta is -0.93, so Biostage's price volatility has been lower than the market average.
| Beta (1Y) | -0.93 |
| 52-Week Price Change | +36.47% |
| 50-Day Moving Average | 6.02 |
| 200-Day Moving Average | 5.90 |
| Average Volume (30 Days) | 1,380 |
Short Selling Information
The latest short interest is 121,658, so 1.04% of the outstanding shares have been sold short.
| Short Interest | 121,658 |
| Short Previous Month | 201,811 |
| Short % of Shares Out | 1.04% |
| Short % of Float | 2.35% |
| Short Ratio (days to cover) | 3.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.56M |
| Pretax Income | -11.30M |
| Net Income | -11.30M |
| EBITDA | -11.26M |
| EBIT | -11.30M |
| Earnings Per Share (EPS) | -$1.09 |
Balance Sheet
The company has $2.97 million in cash and $88,000 in debt, giving a net cash position of $2.88 million or $0.25 per share.
| Cash & Cash Equivalents | 2.97M |
| Total Debt | 88,000 |
| Net Cash | 2.88M |
| Net Cash Per Share | $0.25 |
| Equity / Book Value | 2.21M |
| Book Value Per Share | 0.19 |
| Working Capital | 1.74M |
Cash Flow
In the last 12 months, operating cash flow was -$3.37 million and capital expenditures -$8,000, giving a free cash flow of -$3.38 million.
| Operating Cash Flow | -3.37M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -3.38M |
| FCF Per Share | -$0.30 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biostage does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -16.45% |
| FCF Yield | -4.92% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | -1.34% |
| Buyback Yield | -15.99% |
| Shareholder Yield | -15.99% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Sell |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 22, 2017. It was a reverse split with a ratio of 1:20.
| Last Split Date | Dec 22, 2017 |
| Split Type | Reverse |
| Split Ratio | 1:20 |